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Background:  The  G1P[8]  rotaviruses  are  a  common  cause  of  rotavirus  diarrhoea  among  children  in India.
Two  rotavirus  vaccines  licensed  in  India,  Rotarix  and RotaTeq,  contain  strains  with  G1 and  P[8] genotypes.
A  comparative  analysis  of  these  genotypes  in the live  rotavirus  vaccines  with  circulating  rotavirus  strains
is essential  for assessment  of rotavirus  diversity.
Methods: G1P[8]  strains  detected  during  rotavirus  surveillance  among  diarrhoeic  children  hospitalized
in  Pune  in  1992–1993  and  2006–2008,  were  included  in  the  study.  Ampliﬁcation,  sequencing  and  phylo-
genetic  analysis  of  the  VP7  and VP4  genes  were  carried  out for identiﬁcation  of the  G1 and  P[8] lineages,
respectively.  Antigenic  epitopes  of  VP7  and VP4  encoded  proteins  were  compared  to determine  the
differences  between  the  G1P[8]  strains  from  Pune  and the  vaccine  strains.
Results:  G1-Lineage  1, P[8]-Lineage  3 strains  were  predominant  in  Pune  during  1992–1993 and
2006–2008.  Strains  of  G1-Lineage  2, P[8]-Lineage  3 and  G1-Lineage  1, P[8]-Lineage  4 were  detected
at  low  levels  during  2006–2008.  The  G1-Lineage  1,  P[8]-Lineage  3 strains  showed  up to  eight amino
acid  changes,  each  in  the  VP7  and  VP4  epitopes,  with  respect  to  the Rotarix  vaccine  strain  (G1-Lineage
2,  P[8]-Lineage  1)  and  the  G1  (Lineage-3)  and  P[8]  (Lineage  2) components  of the  RotaTeq  vaccine.  The
G1-Lineage  2  strains  were  closer  to both  vaccine  strains  with  no  or only  two  amino  acid  substitutions  in
the VP7  epitopes.  The  divergent  P[8]-Lineage  4 (OP354-like)  strains  showed  fourteen  and  ﬁfteen  amino
acid  differences,  with  Rotarix  and  RotaTeq  vaccine  strains,  respectively,  in  the VP4  epitopes.
Conclusion:  The  differences  between  the  G1P[8]  strains  in  Pune  and  the  G1  and  P[8]  components  of
the  vaccine  strains  need  to  be  described  for  appropriate  evaluation  of  vaccine  shedding.  Continuous
monitoring  of  the G1P[8]  subgenotypic  lineages  would  be  necessary  to  study  any  long  term  impact  of
vaccine  use on G1P[8]  strain  evolution.
© 2014  Published  by Elsevier  Ltd.  This  is an  open  access  article  under the  CC  BY-NC-ND  license. Introduction
Rotavirus is the most important cause of severe diarrhoeal ill-
ess in infants and young children, worldwide [1]. Annually, in
ndia, rotaviral diarrhoea causes an estimated 122,000–153,000
eaths, 457,000–884,000 hospitalizations and 2,000,000 outpa-
ient visits in children less than ﬁve years of age [2]. Rotaviruses,
f the family Reoviridae,  are triple-layered particles (TLPs) con-
isting of the outer capsid, inner capsid and core. The rotavirus
enome consists of 11 dsRNA segments which code for the six struc-
ural (VP1-VP4, VP6, VP7) and ﬁve non-structural (NSP1-NSP5)
∗ Corresponding author. Tel.: +91 020 26006251; fax: +91 020 26122669.
E-mail address: drshobha.niv@gmail.com (S.D. Chitambar).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.080
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC B(http://creativecommons.org/licenses/by-nc-nd/3.0/).
proteins. The outer capsid proteins, VP7 and VP4, serve as viral
attachment proteins and neutralization antigens [3]. VP4 is acti-
vated by proteolytic cleavage into two  fragments—VP8* and VP5*.
VP8* forms a globular attachment domain at the tip of the VP5*
stalk [4]. A binary system classiﬁes group A rotaviruses into 27
G and 37 P types [5,6], a classiﬁcation initially based on neu-
tralization speciﬁcities of VP7 (Glycoprotein) and VP4 (Protease
sensitive protein). Globally, G1P[8], G2P[4], G3P[8], G4P[8] and
G9P[8] genotype combinations of rotavirus strains are the most
common cause of human infections [7]. Of these, G1P[8] strains
are most predominant (37.7%) [7]. These strains exhibit diver-
sity in the form of 11 G1 and 4 P[8] subgenotypic lineages [8,9].
According to a multi-centre hospital-based study carried out in
India from 2005 to 2009, G1P[8] strains were highly prevalent
[10].
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Two rotavirus vaccines, Rotarix and RotaTeq, are currently
icensed in many countries including India. Rotarix is a monovalent
accine containing the attenuated human G1P[8] rotavirus strain
9-12. RotaTeq is a pentavalent vaccine containing ﬁve human-
ovine reassortant rotavirus strains, each representing one human
enotype—WI79-9 (G1), SC2-9 (G2), WI78-9 (G3), BrB-9 (G4) and
I79-4 (P[8]). Studies from different countries have revealed that
he G1 and P[8] subgenotypic lineages included in these vaccines,
revalent at the time of vaccine development (1980s), are not pre-
ominant today [8,9,11–23].
Earlier, we have reported identiﬁcation of different lineages
ithin VP7 gene of G1 rotaviruses circulating in Pune, western
ndia [24]. The study did not include analysis of the corresponding
[8] lineages of VP4 genes and the rotavirus vaccine strains, 89-12
Rotarix G1P[8]), WI79-9 (RotaTeq G1) and WI79-4 (RotaTeq P[8])
ere not compared due to the unavailability of their sequence data
t the time. The aim of the present study was to assess the diver-
ity of G1P[8] rotavirus strains circulating among children with
iarrhoea in Pune during the two time periods, 1992–1993 and
006–2008, and compare sequences with the G1 and P[8] compo-
ents of vaccines.
. Materials and methods
.1. Specimen selection
A surveillance program for rotavirus disease and strains was car-
ied out in children (<5 years), hospitalized for diarrhoea in Pune
ity during 1990s and 2000s [10,25] (Table 1). The G1P[8] rotavirus
trains identiﬁed during the years 1992 (n = 8), 1993 (n = 11), 2006
n = 21), 2007 (n = 29) and 2008 (n = 13) were selected in the present
tudy for further characterization.
.2. Ampliﬁcation and sequencing of the VP7 and VP4 genes
Viral RNA was isolated from 30% (w/v for solid and v/v for liq-
id) stool suspensions of the selected G1P[8] rotavirus positive
aecal specimens using TRIzol (Invitrogen, U.S.A). Ampliﬁcation of
he complete VP7 gene (1062 bp) was carried out using the primers
eg9 and End9 [26] as described previously [24]. The partial VP4
ene (VP8* region: 10 to 729 bp) was ampliﬁed with primers con2
nd con3 [27] using One-step RT-PCR kit (Qiagen, Germany). The
CR conditions involved an initial reverse transcription step of
0 min  at 45 ◦C, followed by PCR activation at 95 ◦C for 15 min, 40
ycles of ampliﬁcation (1 min  at 94 ◦C, 1 min  at 50 ◦C and 2.5 min
t 70 ◦C) with a ﬁnal extension of 7 min  at 70 ◦C. The VP7 and VP8*
mplicons were sequenced as reported previously [24].
Sequencing of the complete VP4 genes was carried out
s described earlier [28] for six G1P[8] strains (NIV-0613158,
IV-06361, NIV-061060, NIV-0715880, NIV-07523, NIV-083375)
epresenting each of the two P[8] lineages (P[8]-3 and P[8]-4) iden-
iﬁed in Pune on the basis of VP8* sequences.
.3. Nucleotide sequence accession numbers
The VP7 sequences were submitted to GenBank under the
ccession numbers DQ886943-46, DQ886953-56, DQ886958,
Q886959, DQ886962, DQ886964-68, DQ886972, DQ875602,
J948829-55, JN192054-55, JN192060-61, JN192063-64,
N192068-69, JN192071-75, JN192079, JN192082-83, JN192086,
N192089, JN192093-96, JN192098-99, JN192100-01, JN192112-
3, JN192115-16, JN192119-26 and JN192128-31. The VP4
equences were submitted under the accession numbers
Q881499 to HQ881575, EU984107 and HM467806-08.2S (2014) A75–A83
2.4. Phylogenetic analysis
The VP7 and VP4 sequences of the G1P[8] reference strains [8,9]
representing each of the 11 G1 and 4 P[8] subgenotypic lineages
and the sequences of the Rotarix and RotaTeq vaccine strains were
retrieved from GenBank. The sequences available in GenBank for
G1P[8] strains from other cities [Kolkata (n = 8), Delhi (n = 3) and
Manipur (n = 4)] included in the study were classiﬁed into lineages
during comparative analysis.
Multiple sequence alignments were conducted using the
ClustalW implementation in MEGA 5.05 [29]. Phylogenetic trees
were constructed using the neighbour joining algorithm and
Kimura 2-parameter model in MEGA 5.05. The statistical signif-
icance of the genetic relationships was  estimated by bootstrap
resampling analysis (1000 replications). Nucleotide and amino acid
distances were calculated using Kimura 2-parameter model and
P-distance model, respectively.
3. Results
3.1. Distribution of the G1P[8] rotavirus strains circulating in
Pune into subgenotypic lineages
Phylogenetic analysis of the VP7 (Fig. 1(A)) and VP4 genes
(Fig. 1(B)) showed clustering of the G1P[8] strains from Pune into
G1-Lineage 1 or 2 and P[8]-Lineage 3 or 4 (Fig. 2). All the strains from
the years 1992 (8/8, 100%) and 1993 (11/11, 100%) were placed
into G1-Lineage 1, P[8]-Lineage 3. In the year 2006, the G1P[8]
strains from Pune were distributed into G1-Lineage 1, P[8]-Lineage
3 (20/21, 95.2%) and G1-Lineage 2, P[8]-Lineage 3 (1/21, 4.8%). In
2007, while the G1-Lineage 1, P[8]-Lineage 3 strains continued to
predominate (23/29, 79.3%), the prevalence of G1-Lineage 2, P[8]-
Lineage 3 strains increased (5/29, 17.2%). In addition, one strain of
G1-Lineage 1, P[8]-Lineage 4 (1/29, 3.5%) was  detected. In 2008, the
G1P[8] strains from Pune were distributed into G1-Lineage 1, P[8]-
Lineage 3 (12/13, 92.3%) and G1-Lineage 1, P[8]-Lineage 4 (1/13,
7.7%).
Phylogenetic analysis of the G1P[8] strains from other cities in
India (Fig. 1(A) and (B)) revealed circulation of the same subgeno-
typic lineages as in Pune. All G1P[8] strains from Kolkata (8/8,
2008–2009) and Delhi (3/3, 2000s) clustered into G1-Lineage 1,
P[8]-Lineage 3. The G1P[8] strains from Manipur (2006–2007) were
distributed into G1-Lineage 1, P[8]-Lineage 3 (2/4) and G1-Lineage
1, P[8]-Lineage 4 (2/4).
The Rotarix vaccine strain, 89-12, clustered into G1-Lineage 2,
P[8]-Lineage 1. The WI79-9 (G1) strain of RotaTeq vaccine was
placed in G1-Lineage 3 while the WI79-4 (P[8]) strain was classiﬁed
in P[8]-Lineage 2 (Fig. 1(A) and (B)).
3.2. Comparative sequence analysis of VP7 and VP4 genes of
rotavirus G1P[8] strains from Pune and rotavirus vaccines
The G1-Lineage 1 strains showed 92.8–95.2% nucleotide and
92.9–95.4% amino acid identity with the Lineage 2 of G1 Rotarix
vaccine strain and 89.9–92.0% nucleotide and 92.0–94.4% amino
acid identity with the Lineage 3 of the G1 strain in RotaTeq vaccine.
The G1-Lineage 2 strains were closer to the Rotarix VP7 of the same
lineage (97.3–97.5% nucleotide and 97.2–97.5% amino acid iden-
tity) than to the RotaTeq VP7 of Lineage 3 (92.1–92.2% nucleotide
and 94.4–94.8% amino acid identity).
The VP8* of the P[8]-Lineage 3 strains were more similar to the
RotaTeq P[8] (92.3–93.9% nucleotide and 92.9–95.8% amino acid
identity) than to Rotarix VP8* (89.5–91.4% nucleotide and 90.8-
93.3% amino acid identity). The divergent P[8]-Lineage 4 strains
showed lower identities with both the vaccine strains (Table 2).
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Fig. 1. Phylogenetic dendrogram of the nucleotide sequences representing G1P[8] rotavirus strains circulating in Pune, India.
(A)  VP7 (coding region: 49–1026 bp) and (B) VP4 (VP8* region: 10–729 bp)
The  strains from Pune are indicated by a solid triangle while the vaccine strains are indicated by a solid circle. Bootstrap values ≥70% are shown. The GenBank accession
numbers for the VP7 gene sequences of the reference G1 rotavirus strains are AY631049 (Dhaka 8-02), DQ512979 (Thai-804), U26370 (Cos-70), K02033 (Wa), U26378
(Kor-64), DQ377573 (PA5/90), AB018697 (AU19), U26366 (Ban-59), U26373 (Egypt-7), DQ377574 (PA32/90), AF426162 (SW20/21), L24164 (C60). The GenBank accession
numbers for the VP4 gene sequences of the reference P[8] rotavirus strains are L34161 (Wa), U30716 (F45), AJ605320 (Hun9), AJ302148 (OP354). The GenBank accession
numbers for the sequences of the vaccine strains are JN849114 (Rotarix VP7), JN849113 (Rotarix VP4), GU565057 (RotaTeq G1 VP7), GU565044 (RotaTeq P[8] VP4). Rep-
resentative strains from Kolkata, Delhi and Manipur have also been included in the dendrogram. The VP7 gene sequences for the strains from Kolkata are available under
the  accession numbers AB561878 (GRAVP736), AB553330 (GRAVP732), AB553329 (GRAVP731), AB553328 (GRAVP730), AB551663 (GRAVP728), AB550709 (GRAVP727),
AB550233 (GRAVP720), AB547709 (GRAVP718) while the VP4 sequences are available under the accession numbers AB561881 (GRAVP436), AB553327 (GRAVP432),
AB553326 (GRAVP431), AB553325 (GRAVP430), AB551661 (GRAVP428), AB550708 (GRAVP427), AB544058 (GRAVP420), AB544056 (GRAVP418). The accession numbers for
the  VP7/VP4 sequences of the strains from Delhi are FJ827595/FJ827605 (Dan279), FJ827593/FJ861662 (Dan114), FJ827592/FJ827602 (Dan103) while those for the strains
from  Manipur are GQ229043/GQ240617 (mani-375/07), GQ229042/GQ240616 (mani-365/07), GQ229041/GQ240614 (mani-140/06), GQ229040/GQ240612 (mani-63/06).
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Fig. 1. (Continued ).
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Table  1
Year wise details of the rotavirus surveillance carried out among children (<5 years) hospitalized for diarrhoea in Pune city during 1992–1993 and 2006–2008.
Year No. of faecal specimens
collected
No. (%) of rotavirus
positive specimens
No. of specimens subjected
to genotypinga
No. (%) of specimens positive
for G1P[8] rotavirus
1992 144 32 (22.2) 16 8 (50.0)b
1993 335 104 (31.0) 38 11 (28.9)b
2006 301 96 (31.9) 96 27 (28.1)
2007 311 137 (44.1) 137 64 (46.7)
2008 231 65 (28.1) 65 13 (20.0)
a Genotyping has been carried out by multiplex PCR.
b Number of specimens subjected to genotyping was considered as denominator for pe
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Pig. 2. Distribution of the G1P[8] rotaviruses circulating in Pune into subgenotypic
ineages.
oth P[8] lineages showed higher amino acid divergence in VP8*
egion than in VP5* region (Table 2).
.3. Comparison of the VP7 and VP4 antigenic epitopes of the
1P[8] rotavirus strains from Pune and rotavirus vaccines
The rotavirus VP7 protein consists of two antigenic epitopes:
-1 (7-1a and 7-1b) and 7-2 encompassing 29 amino acid residues
30]. The G1-Lineage 1 strains from Pune showed 3–6 amino acid
ifferences with the G1-Lineage 2 strain of Rotarix and 5–8 amino
cid differences with the G1-Lineage 3 strain of RotaTeq vaccine
Table 3). The majority (92.1–100%) of the G1-Lineage 1 strains
howed three and one amino acid differences, respectively, in epi-
opes 7-1a (N94S, S123N, K291R) and 7-2 (M217T/I) in comparison
ith both vaccine strains. All amino acid differences were com-
on  to the G1-Lineage 1 strains of both periods (1992–1993 and
006–2008) with the exception of the substitution L148F in epitope
-2 that was restricted to seven strains from the years 2006–2008.
n addition, all G1-Lineage 1 strains had the substitutions D97E (epi-
ope 7-1a) and S147N (epitope 7-2) when compared to the G1 strain
f RotaTeq vaccine. Strain speciﬁc differences were noted at amino
cid positions 125, 129 (epitope 7-1a), 212, 213 (epitope 7-1b) and
able 2
ercent nucleotide and amino acid identities between the VP4 genes of G1P[8] rotavirus 
Rotavirus straina/P[8]
lineage
Percent nucleotide/amino acid identity with VP4 g
Rotarix 
VP8* VP5* Comp
NIV-06361/P[8]-3 90.9/92.1 88.6/95.1 89.4/9
NIV-061060/P[8]-3 91.0/92.9 89.2/95.3 89.7/9
NIV-0613158/P[8]-3 90.9/92.1 90.3/95.6 90.5/9
NIV-0715880/P[8]-3 90.2/91.2 89.2/95.6 89.5/9
NIV-07523/P[8]-4 87.0/87.0 88.4/94.7 88.0/9
NIV-083375/P[8]-4 86.8/87.0 88.6/94.9 88.1/9
a Six representative strains for which complete VP4 sequencing was done, are shown ircentage calculation.
221 (epitope 7-2) in a few (1–3) of the G1-Lineage 1 strains on
comparison with both vaccine strains.
The G1-Lineage 2 strains detected in Pune during 2006 and
2007 showed 100% sequence identity to the Rotarix vaccine strain
(G1-Lineage 2) in the VP7 epitopes. With respect to the RotaTeq vac-
cine strain, the G1-Lineage 2 strains showed only two amino acid
differences–D97E (epitope 7-1a) and S147N (epitope 7-2) (Table 3).
Overall, the epitopes 7-1a and 7-2 were more prone to variations
than epitope 7-1b among all G1 strains.
The VP4 protein of rotavirus consists of nine antigenic
epitopes—four (8-1 to 8-4) in VP8* and ﬁve (5-1 to 5-5) in VP5*,
which together include 37 amino acids [31,32]. The P[8]-Lineage
3 strains from Pune showed 5-8 amino acid differences with the
P[8]-Lineage 1 strain of Rotarix and 2-5 amino acid differences with
the P[8]-Lineage 2 strain of RotaTeq vaccine in the VP8* antigenic
epitopes (Table 4A). These comprised S146G, S190N and N196G
in epitope 8-1 and N113D, S125N, S131R, N135D in epitope 8-3 as
compared with Rotarix vaccine strain. With regard to the P[8] strain
of RotaTeq vaccine, the P[8]-Lineage 3 strains of this study showed
three and one amino acid differences, respectively, in epitopes 8-1
(S146G, N190S, D196G) and 8-3 (N113D). Strain speciﬁc differences
were noted at the amino acid positions 192, 193, 195 (epitope 8-1),
and 114, 115,116 (epitope 8-3) in a few (1-5) of the P[8]-Lineage
3 strains on comparison with both vaccine strains. Epitopes 8-2
and 8-4 were completely conserved. The amino acid substitutions
in VP8* region were common to all P[8]-Lineage 3 strains at both
time points (1992–1993 and 2006–2008).
To compare VP5* epitopes of the P[8]-Lineage 3 strains, we  used
complete VP4 sequences available for four P[8]-Lineage 3 strains,
NIV-0613158, NIV-06361, NIV-061060, NIV-0715880 (Table 4B).
These strains showed 1-2 amino acid differences (Y386D in all four
strains, S388N in one strain, NIV-061060) with Rotarix and 2-3
amino acid differences (R384S, H386D in all four strains, S388N
in NIV-061060) with RotaTeq in epitope 5-1. Epitopes 5-2 to 5-5
showed no variations (Table 4B).
The P[8]-Lineage 4 strains, detected in Pune during 2007 andshowed fourteen amino acid differences (twelve in VP8* and two
in VP5*) with the Rotarix vaccine strain and ﬁfteen amino acid dif-
ferences (twelve in VP8* and three in VP5*) with the P[8] strain of
strains from Pune and rotavirus vaccines.
ene from vaccine strains
RotaTeq
lete VP4 VP8* VP5* Complete VP4
4.2 93.9/95.8 91.5/95.8 92.2/95.9
4.4 93.1/95.0 91.4/95.6 91.8/95.4
4.6 92.8/94.1 93.1/96.0 93.0/95.5
4.2 92.6/94.1 92.0/96.4 92.1/95.6
2.5 87.8/88.7 87.5/93.9 87.7/92.5
2.6 87.6/88.7 87.3/93.7 87.4/92.4
n the table.
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Table 3
Alignment of the amino acid residues in VP7 antigenic epitopes of the G1P[8] rotavirus strains circulating in Pune and rotavirus vaccines.
Table includes representative G1P[8] strains from children in Pune. The G1P[8] strains from adolescents and adults in Pune also showed the same lineage-speciﬁc amino
acid  substitutions (data not shown). Representative G1P[8] strains from Kolkata (GRAVP732, GRAVP731, GRAVP727, GRAVP718), Delhi (Dan279, Dan103) and Manipur
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cid  residues that differ from Rotarix are shown in yellow colour while those that d
nd  RotaTeq are in green colour. The amino acid positions described previously [30
otaTeq vaccine (Table 4A and B). The variability between the P[8]-
ineage 4 and the vaccine strains was restricted to the epitopes 8-1,
-2, 8-3 and 5-1 while the epitopes 8-4, 5-2 to 5-5 were completely
onserved.
Comparison of the VP7 and VP4 epitopes of the G1-Lineage1,
[8]-Lineage 3 strains reported from adolescents and adults in Pune
33,34], showed the same amino acid variations (data not shown)
ith respect to the vaccine strains as were noted in the present
tudy (Tables 3 and 4) for the G1-Lineage 1, P[8]-Lineage 3 strains
rom children in Pune.
Classiﬁcation (Fig. 1(A) and (B)) and epitope analysis of the
1P[8] strains from Kolkata (2008–2009), Delhi (2000s) and
anipur (2006–2007) showed the same lineage-speciﬁc amino
cid substitutions in the VP7 and VP4 epitopes, as noted for the
trains from Pune (Tables 3 and 4). An earlier study of P[8] lin-
ages of G1P[8] strains from Kolkata has described the circulation of
[8]-Lineages 3 and 4 during 2004–2005 [35]. These P[8]-Lineage 3
ISO115, ISO114, ISO113, 27B3) and P[8]-Lineage 4 (ISO117, ISO116,
7B3) strains also showed the same lineage-speciﬁc sequence vari-
tions in the VP8* epitopes (Table 4A).
. Discussion
The World Health Organization has recommended inclusion of
otavirus vaccines in national immunization programs worldwide,
specially in countries like India where diarrhoea is responsible for
10% mortality in children [36]. Two vaccines, Rotarix and RotaTeq
re currently licensed for use against rotavirus. In India, Rotarix was
aunched in 2008 and RotaTeq in 2011. Both vaccines are availables between Rotarix and RotaTeq vaccine strains are shown in pink colour. The amino
om RotaTeq are in blue colour. The amino acid residues different from both Rotarix
utralization escape mutation sites are shown in red colour.
through the private sector. However, they have not been introduced
into the national immunization program [37]. The Indian Academy
of Paediatrics Committee on Immunization (IAPCOI) recommends
administration of either of the vaccines to children with consent
from the parents [38]. According to a nationally representative sur-
vey carried out during 2009–2010, 9.7% of sampled paediatricians
in India reported routine administration of rotavirus vaccine [39].
However, given that the majority of childhood immunization is
delivered by the public sector, data on rotavirus vaccine coverage
in India is not currently available.
The mechanisms of protection against rotavirus after vaccina-
tion are not fully understood. This has resulted in the adoption of
different approaches to the development of broadly protective vac-
cines. The RotaTeq vaccine (pentavalent) is based on the concept
that genotype speciﬁc neutralizing antibodies against the rotaviral
outer capsid proteins VP7 and VP4 are the primary determinants of
protection and thus includes VP7 and VP4 components of the major
human rotavirus genotypes [40]. The Rotarix vaccine (monovalent
G1P[8]), on the other hand, is based on the theory that protec-
tive immune response could be stimulated by B- or T-cell epitopes
present on any rotaviral protein, and these epitopes may  be con-
served among different rotavirus VP7 and VP4 genotypes [40]. Both
the vaccines have demonstrated efﬁcacy against a range of geno-
types in the developed countries [41–43].
The success of the rotavirus vaccines in India will depend on
their ability to provide protection against the rotavirus strains
prevalent in the country. G1P[8] rotavirus strains are predominant
in India and are represented in both the current vaccines. In this
study, we  investigated the intragenotypic differences between the
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Table  4
Alignment of the amino acid residues in (A) VP8* and (B) VP5* antigenic epitopes of the G1P[8] rotavirus strains circulating in Pune and rotavirus vaccines.
Table includes representative G1P[8] strains from children in Pune. The G1P[8] strains from adolescents and adults in Pune also showed the same lineage-speciﬁc amino
acid  substitutions (data not shown). Representative G1P[8] strains from Kolkata (GRAVP432, GRAVP431, GRAVP427, GRAVP418, ISO114, 47B3), Delhi (Dan279, Dan103) and
Manipur (mani-375/07, mani-140/06) are also included for comparison. The amino acid differences between Rotarix and RotaTeq vaccine strains are shown in pink colour.
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sly [31, 32] as neutralization escape mutation sites are shown in red colour.
(Tables 3 and 4). Such amino acid variations between the differ-
ent subgenotypic lineages warrant further investigation as they
may  ultimately affect vaccine efﬁcacy, particularly if protection
is mediated primarily by VP7 and VP4 genotype speciﬁc immune
responses.
Antigenic differences have been reported previously between
the G1-Lineage 2 and Lineage 3 strains which share 95.9–96.5%
amino acid identity in VP7 protein and differ at the amino acid
A ccine 3
p
G
l
q
p
o
t
b
o
n
p
H
o
o
a
m
4
T
a
i
s
v
l
(
i
v
V
G
e
v
a
i
c
i
t
s
s
c
i
d
w
R
t
G
I
t
t
n
r
e
t
r
C
A
o
[
[
[
[
[
[
[
[
[
[
[
[
[82 R. Kulkarni et al. / Va
ositions 97 and 147 in the VP7 epitopes. Antisera raised against the
1-Lineage 3 strain, D, neutralized another strain (Wa) of the same
ineage more efﬁciently than G1-Lineage 2 strains [44]. This raises
uestions of antigenic variability between the G1-Lineage 1 strains
revailing in India and G1-Lineages 2 (Rotarix) and 3 (RotaTeq)
f rotavirus vaccine strains and the immune response induced by
hem.
A study conducted to examine the antigenic differences
etween the strain MX08-659 of P[8]- Lineage 3 and the Wa strain
f P[8]-Lineage 1, has described the use of truncated recombi-
ant VP8* peptides from each of these strains and suggested the
resence of conserved epitopes in the VP8* variable region [45].
owever, in the present study, comparison of the VP8* epitopes
f the P[8]-Lineage 3 strains from India with the vaccine strains
f P[8]-Lineage 1 (Rotarix) or Lineage 2 (RotaTeq) revealed amino
cid differences (Table 4A and B) at known neutralization escape
utation sites [31,32].
Rotavirus strains belonging to the G1-Lineage 1, P[8]-Lineage
 (Figs. 1 and 2) have been identiﬁed in India during the 2000s.
he antigenic properties of the P[8]-Lineage 4 or OP354-like strains
re not well understood. The P[8]-Lineage 4 strains are being
ncreasingly detected worldwide [13,16,17,20,21,46–48] leading to
peculation about the long term protective effect of the current
accines against this divergent lineage.
The G1-Lineage 1, P[8]-Lineage 3 strains, indicating the same
ineage-speciﬁc amino acid substitutions noted in the present study
Tables 3 and 4), are currently in circulation worldwide [8,9,11–23]
ncluding in Europe and America wherein the efﬁcacy of rotavirus
accines is high [41–43]. Thus, sequence differences in VP7 and
P4 encoding genes, between the circulating G1P[8] strains and the
1, P[8] components of vaccine strains, do not seem to render any
ffect as yet on vaccine efﬁcacy in these countries. In fact, Rotarix
accine (monovalent G1P[8]) has been shown to be effective even
gainst non-G1P[8] rotavirus strains [42,43]. Antibodies against
mmunorecessive neutralization epitopes in VP7 and VP4 which are
onserved between genotypes and/or immune responses against
nternal or non-structural proteins are thought to be responsible for
his apparent cross-protection [40]. Although both vaccines have
hown substantial utility in Europe and America to date, it has been
uggested that their long term use may  result in selection of strains
apable of escaping vaccine-induced immunity [49]. It is worth not-
ng that, after the introduction of Rotarix vaccine in Belgium, the
ecrease of G1P[8] strains belonging to lineages closer to Rotarix
as more than the decrease of G1P[8] strains distantly related to
otarix [50].
In conclusion, the present study describes differences between
he G1P[8] rotavirus strains circulating in Pune, India and the
1 and P[8] components of the Rotarix and RotaTeq vaccines.
n order to understand the signiﬁcance of these differences and
heir inﬂuence if any, on vaccine efﬁcacy, further investigation of
he intragenotype antigenic variability and the protective mecha-
ism of vaccines would be necessary. Any increase in use of the
otavirus vaccines in India, may  have long term effects on strain
volution leading to emergence of novel strains. This warrants con-
inuous monitoring of the subgenotypic lineages within the diverse
otavirus G1P[8] strains.
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